Abstract
A Sindbis virus replicon-based DNA vaccine containing VP2 gene of canine parvovirus (CPV) was delivered by Escherichia coli to elicit immune responses. The orally immunized dogs developed CPV-specific serum IgG and virus neutralizing antibody responses. The cellular immune responses analyzed using lymphocyte proliferation test and flow cytometry indicated CPV-specific sensitization of both CD3+CD4+ and CD3+CD8+ lymphocytes. This study demonstrated that the oral CPV DNA vaccine delivered by E. coli can be considered as a promising approach for vaccination of dogs against CPV.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Administration, Oral
-
Animals
-
Antibodies, Neutralizing / blood
-
Antibodies, Viral / blood
-
Capsid Proteins / genetics
-
Capsid Proteins / immunology*
-
Cell Line
-
Dog Diseases / immunology
-
Dog Diseases / prevention & control
-
Dog Diseases / virology
-
Dogs
-
Escherichia coli / genetics
-
Immunization
-
Immunoglobulin G / blood
-
Lymphocyte Activation / immunology
-
Parvoviridae Infections / immunology
-
Parvoviridae Infections / prevention & control
-
Parvoviridae Infections / veterinary*
-
Parvoviridae Infections / virology
-
Parvovirus, Canine / genetics
-
Parvovirus, Canine / immunology
-
Replicon / genetics
-
Sindbis Virus / genetics*
-
Vaccines, DNA / administration & dosage
-
Vaccines, DNA / genetics
-
Vaccines, DNA / immunology*
-
Viral Vaccines / administration & dosage
-
Viral Vaccines / genetics
-
Viral Vaccines / immunology*
Substances
-
Antibodies, Neutralizing
-
Antibodies, Viral
-
Capsid Proteins
-
Immunoglobulin G
-
Vaccines, DNA
-
Viral Vaccines